FEM1B

Across TCGA pan-cancer cohorts, FEM1B mass-spec protein differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of FEM1B’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where FEM1B mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types FEM1B is over-expressed in tumor, although a few such as LUAD show the opposite, repressed pattern.

HNSC, LUAD, and PDAC are the cancer types where FEM1B tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in FEM1B mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	III,IV	+0.309	<.001	9	view →
LUAD	All	All	−0.160	<.001	4	view →
PDAC	Female	All	+0.827	.009	3	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

FEM1B–HNSC

Open the HNSC breakdown →